Changing Lives, One Cup at a Time
Currently Browsing: Natural Collagen Concentrate

Protect Your Joints from AutoImmune Attack

More than 52 million Americans suffer from some form of arthritis.

Conventional medical wisdom has long held that rheumatoid arthritis results from an autoimmune attack on joints, while osteoarthritis was thought to result from age-related “wear-and-tear.”

For the first time, a team of researchers at Stanford University has demonstrated that this is not true!

It turns out that osteoarthritis is accompanied by the same pathological, pro-inflammatory immune factors involved in rheumatoid arthritis. Even more compelling was their finding that, if treatment is initiated before symptoms manifest, osteoarthritis may be entirely prevented.

Unfortunately, the list of available drugs to combat autoimmune disorders—including long-term treatment with corticosteroids like prednisone—is notoriously limited and comes with life-threatening complications, including obesity and diabetes.

The exciting news is a novel intervention has been identified that safely regulates the immune system to protect aging joint tissue from autoimmune attacks.

In this article, you will learn about natural collagen concentrate (NCC). Its unique molecular characteristics prevent immune cells’ overreaction to proteins normally found in cartilage and joint tissue that lead to pain and stiffness in both rheumatoid and osteoarthritis.

In multiple clinical trials using this proprietary collagen formulation, scientists at Harvard have been able to achieve relief of arthritic symptoms, with some patients experiencing complete remission!

You will also learn how NCC’s mode of action may be synergistically enhanced when combined with Boswellia serrata and two other joint-renewing nutrients.

The Stanford team’s discovery of the autoimmune link between osteoarthritis and rheumatoid arthritis was first presented in late 2011.

A group of 25 scientists concluded that the development of osteoarthritis is in great part driven by low-grade inflammatory processes. Specifically, the researchers discovered that the body launches an orchestrated, powerful attack on the synovial joints via signaling proteins normally used to fight infections. This autoimmune response, they reported, plays a key role in osteoarthritis onset.

Synovial joints are the most common joint types in the human body. They contain soft-tissue cushioning in addition to cartilage, along with synovial fluid, a natural lubricant. Knees, hips, and shoulders are just a few of the commonly arthritic joints that fall into this category.

What the Stanford team found was that low-grade inflammation is not merely an early symptom of osteoarthritic cartilage destruction in synovial joints—it is the trigger that causes it. The study also revealed that by targeting the autoimmune derangements that occur early on in the development of osteoarthritis, arthritis might be completely preventable.

They went on to point out that drugs intended to inhibit the arthritic reaction (like corticosteroids) paradoxically compromise the immune system. It would be far safer, they reported, if a natural way to turn off the body’s abnormal response were available.

Novel Method to Target the Pathologic Immune Response

Here’s how it works.These compelling new findings coincided with the development of a naturalintervention shown to protect tissues in aging joints called undenatured type II collagen.

Joints are lined with cartilage that both lubricates joints and absorbs physical impacts, preserving ease of motion and comfort. The bulk of the cartilage in your joints consists of collagen, a biomolecular protein critical to reducing friction and keeping joints youthful.

Osteoarthritis and rheumatoid arthritis both involve the structural degradation and gradual destruction of cartilage in aging joints. Osteoarthritis was long thought to be a consequence of simple “wear- and-tear” on joints (and hence largely inevitable). Rheumatoid arthritis, on the other hand, was recognized as an inflammatory autoimmune disease that arises when the body mistakenly attacks its own tissues, in this case the joint linings and cartilage.

We now know that both arise from pro-inflammatory immune factors.

Intrinsic to this process is the mobilization of “killer” T-cells into the joints by exposed collagen within the synovial lining.

Under normal conditions, collagen elicits no immune response. It is exposed collagen that immune cells mistakenly identify as invasive, foreign molecules.7 In response to the “threat,” inflammatory cytokines are released that draw in more “killer” T-cells.13 Those cells bombard exposed cartilage with toxic chemicals in order to destroy it, creating oxidative stress and further inflammation in the process.

Over time, these continuous biomolecular insults erode and disintegrate the cartilage that lubricates and functions as a shock-absorber in joints.

The resulting pain can become chronic and debilitating in lockstep with sensations of friction or grinding involved in joint movement. While less acute at rest, this pain is exacerbated by walking, standing, or any form of weight-bearing. Osteoarthritis sufferers often experience joint stiffness or immobility after periods of inactivity, for instance upon waking or after a long period of sitting.

NCC® Triggers Specific Oral Tolerance for Lasting Joint Relief

In both osteoarthritis and rheumatoid arthritis, the chief cause of autoimmune response is exposed collagen and the ensuing attack by sensitized killer T-cells.

Suppose an effective means of regulating killer T-cells before they encountered exposed collagen could be developed? This would “re-train” them to treat exposed collagen as a harmless substance and prevent joint degradation and destruction.

In 2000, the first hint of just such an intervention emerged.

A team of scientists at the University of Nebraska was surprised to find that chicken soup prevented the mobilization of immune system cells to sites of inflammation. Upon further analysis, it was not vegetables but a soluble component of the chicken broth itself that exerted this anti-inflammatory activity.

The researchers believe that it was likely the collagen from chicken bones in the broth that was the source of this beneficial anti-inflammatory effect.

New Way to Combat Rheumatoid and Arthritis

  • The most common joint disease, osteoarthritis, was long viewed as a disease of wear-and-tear. New findings reveal that it is one of a number of disorders caused by an abnormal response of the immune system.
  • Instead of the traditionally prescribed NSAIDs and immune suppressants, a revolutionary and side effect-free form of undenatured type II collagen called NCC® has been shown to desensitize the immune system and prevent pro-inflammatory autoimmune attacks on aging joints.
  • Undenatured type II chicken collagen has been shown in studies to be capable of activating the pathway known as induced oral tolerance, which teaches the immune system to correctly recognize exposed cartilage proteins as the body’s own tissues—instead of foreign microbes—thus preventing an inflammatory attack, a newly recognized cause of osteoarthritis.
  • The anti-inflammatory action of a novel composition of AKBA-enriched Boswellia serrata—and two joint-protective nutrients, glucosamine sulfate and boron, now available in highly bioactive formulations—can further boost the ability of undenatured type II chicken collagen to fight osteoarthritis, the painful condition behind so many visits to primary care physicians. Owing to its particular molecular structure, the chicken-derived type II collagen in UC-II® acts as a kind of “reverse vaccine,” one that regulates the immune system so that it stops mobilizing attacks against proteins normally found in healthy joint cartilage.

It does so by inducing what immunologists call specific oral tolerance—the desensitization of immune response to specific agents via an orally administered intervention. This is why NCC® may be likened to a kind of oral vaccine that reverses T-cell attacks on exposed cartilage.

Scientists at Harvard first studied the effects of NCC® on human patients with rheumatoid arthritis, long established as an autoimmune disorder. In a randomized, double-blind trial of 60 patients, undenatured type II chicken collagen produced a significant decrease in the number of swollen and painful joints within 3 months, compared to the placebo group. In fact, 14% of patients achieved complete remission. No side effects were found.

Later, a much larger study of 274 rheumatoid arthritis patients confirmed this finding, as did a study on patients with juvenile rheumatoid arthritis, a particularly aggressive form of this disease.

Turning their attention to osteoarthritis, scientists tested undenatured type II collagen on horses and dogs. They noted a reduction of 88% in measurable pain among horses given this formulation. In one study, moderately arthritic dogs given the undenatured collagen formulation were able to place more weight on sore limbs, and use them more naturally, relative to those given placebo, or those given chondroitin plus glucosamine.

The gold standard of scientific evidence is a randomized, double-blind, clinical study on humans. In a study of this type involving 52 adult human volunteers with osteoarthritis, who had an average age of 59, scientists found that in just 90 days, undenatured type II chicken collagen produced “significant enhancement in daily activities suggesting an improvement in their quality of life.”

In this trial, using the standardized WOMAC (Western Ontario McMaster Osteoarthritis Index) scale, scientists found that 40 mg a day of undenatured type II chicken collagen reduced osteoarthritis symptoms by 33% in 90 days. By comparison, the combination of 1,500 mg a day of glucosamine and 1,200 mg a day of chondroitin sulfate reduced WOMAC scores by only 14%.

Pain scores on the visual analog scale (VAS) decreased 40% for the collagen group, while pain scores for the glucosamine/chondroitin group decreased just 15%.

Finally, using the Lequesne’s functional index score—which measures pain during daily activities, such as walking—the study team found that undenatured type II collagen reduced this score by 20%, while the combination of glucosamine and chondroitin lowered the score by only 6%. All results were observed in just 90 days.

Why Undenatured Type II Collagen

As discussed earlier, immune system T-cells are tasked with recognizing and distinguishing between “self” molecules and “foreign” ones. They do this important work by responding to very specific molecular shapes and 3-dimensional structures. If T-cells in the blood are simply exposed, without any “training,” to a previously unrecognized protein structure (such as those found on joint collagen) they react violently and trigger a massive inflammatory response to destroy the protein.

This is why, when scientists want to create an animal model of arthritis, they inject collagen into their subjects, sensitizing the T-cells in their blood to the protein. Those circulating T-cells set up inflammation in the animal’s joints, with their rich supplies of collagen.

If T-cells are given adequate preparation, however, they can be “taught” that a specific molecule is a friend rather than a foe. Where does such T-cell “training” take place?

In the intestinal tract, specifically the lower end of the small intestine, which is rich in collections of immune tissue called Peyer’s patches. Peyer’s patches act as “training centers” for T-cells, exposing them to all sorts of molecular shapes that are natural components of the food we eat. In that fashion, we desensitize our immune systems and develop a natural tolerance to new foods without having constant allergic or inflammatory reactions.

So, by providing native collagen of the right 3-dimensional structure to the digestive tract, rather than to the bloodstream directly, we can “educate” our T-cells to ignore collagen when they encounter it in joints. Scientists say that this enables people to develop oral tolerance to collagen.

And oral tolerance to collagen powerfully suppresses joint inflammation, as has been shown in numerous laboratory studies. Oral administration of soluble type II collagen even prevents arthritis induced experimentally by collagen injections.

But not just any collagen works. Typical commercial processing causes collagen to become denatured, uncoiling from its normal helical shape and losing its 3-dimensional structure. Denatured collagen has no beneficial effects on joint inflammation.

A more natural form of collagen, called undenatured type II collagen, or UC-II®, has recently been developed. UC-II® is a highly effective product and a rich source of natural collagen. UC-II® retains its original 3-dimensional molecular structure, keeping it recognizable by T-cells in Peyer’s patches. And UC-II is robust enough to survive the harsh conditions in the stomach and small intestine, arriving at Peyer’s patches with its molecules intact.

Neutralizing the Pro-inflammatory 5-LOX Enzyme

Incorporating a safe anti-inflammatory agent in a joint protection program may provide an additional layer of defense against arthritic damage and pain, by helping to eliminate the immune trigger.

In traditional Indian medicine, the gum resin of Boswellia serrata is associated with alleviating inflammatory diseases such as arthritis. Double-blind, placebo-controlled studies have shown boswellia decreases swelling and pain in patients with osteoarthritis of the knee.

Various compounds within boswellia exert an anti-inflammatory action that is different from most anti-inflammatory agents: they inhibit the pro-inflammatory enzyme 5-lipoxygenase or 5-LOX.

A highly bioactive boswellia compound—called 3-O-acetyl-11-keto-b-boswellic acid, or AKBA—directly binds to and selectively inhibits 5-LOX.21,22 This prevents 5-LOX from facilitating the production of leukotriene, a pro-inflammatory compound that damages cartilage and joints. AKBA also reduces pro-inflammatory leukocyte elastase activity. The problem up to now has been limited bioavailability of AKBA following oral administration.

Fortunately, researchers have developed a boswellia formulation with enhanced bioavailability. Scientists administering this patented boswellia compound to animals found that it increased the bioavailability of AKBA in the systemic circulation by 52%, compared with a standard boswellia extract.

The researchers concluded that the AKBA-rich boswellia product “consistently…confers better anti-inflammatory efficacy,” and “provides more potential benefits in recovering articular cartilage damage… due to inflammatory insult in arthritis such as osteoarthritis or rheumatoid arthritis.”

In a double-blind, randomized, placebo-controlled study on human patients with osteoarthritis, 100 mg of the patented AKBA-enriched boswellia extract inhibited the cartilage-degrading enzyme MMP-3, and exhibited an anti-inflammatory action that was superior to a standard boswellia extract. Benefits were seen as early in the 90-day study as 7 days. The journal-published report described the formulation as a “novel synergistic composition.”


Flex is like ‘chicken soup’ for your joints

A staggering 53 million Americans suffer from arthritis, making it the leading cause of disability in this country.

A nutritional compound has demonstrated the ability to address one of the root causes of joint pain—reducing pain and improving flexibility—with none of the side effects of typical drug treatments.

Called “natural collagen concentrate,” (NCC), this protein compound acts against the autoimmune reactions that can lead to joint pain and degeneration. NCC has been shown effective in previous animal and human studies of arthritis.

A groundbreaking new study shows that NCC can reduce joint pain and improve joint flexibility even in healthy people who experience painful joints after exercise.

An Underlying Cause of Osteoarthritis

While the term “arthritis” can be used to describe several different conditions, the two most common forms are osteoarthritis and rheumatoid arthritis. Rheumatoid arthritis is an autoimmune disease in which the body reacts to components in joint tissue (mainly collagen) to produce inflammation, pain, and disability. Osteoarthritis was traditionally thought to be the result of wear and tear on the joints.10 Recent discoveries, however, have determined that osteoarthritis is accompanied by the same pro-inflammatory immune factors involved in rheumatoid arthritis.

In both conditions, an autoimmune response is caused when the body launches an attack against collagen, the substance that makes up the bulk of the cartilage that lines your joints. Collagen is a protein critical to reducing friction and keeping joints youthful. The problem occurs when microscopic bits of collagen find their way into the bloodstream, at which point immune cells mistakenly identify them as invasive, foreign molecules.

In response to this perceived “threat,” inflammatory cytokines are released that draw in more“killer” T-cells. Those cells bombard exposed cartilage with toxic chemicals in order to destroy it, creating oxidative stress and further inflammation in the process.

Over time, these continuous attacks erode and disintegrate the cartilage that lubricates and functions as a shock-absorber in joints.

The resulting pain can become chronic and debilitating, and can include sensations of friction or grinding involved in joint movement. While less acute at rest, this pain is exacerbated by walking, standing, or any form of weight-bearing. Osteoarthritis sufferers often experience joint stiffness or immobility after periods of inactivity.

Fortunately, scientists have discovered a substance called un-denatured type II collagen, or NCC, that retrains killer T-cells so that they recognize collagen as a harmless substance—preventing the joint damage seen in osteoarthritis.

Reducing Joint Pain and Swelling

NCC was discovered when a team of scientists at the University of Nebraska found that chicken soup prevented the mobilization of immune system cells to sites of inflammation. Upon further analysis, they discovered that it was not vegetables, but a component of the chicken broth itself that exerted this anti-inflammatory activity.

The researchers showed that chicken-derived type II collagen functions to regulate the immune system so that it stops attacking proteins normally found in healthy joint cartilage.

The results have been remarkable.

In a pilot study of people with severe joint pain, a dose of 10 mg/day of this type II collagen (NCC) for 42 days was shown to significantly reduce joint pain and swelling, along with morning stiffness, stiffness following periods of rest, pain that worsens with use of the affected joint, and loss of range of motion and function.

Follow-up studies show NCC reduces joint pain and stiffness that can follow as a result of exercise. Even normal exercise puts stress on joints, which causes the release of collagen fragments into the bloodstream. Since these fragments are partly to blame for post-exercise pain and stiffness, supplementing with NCC can prevent post-exercise pain.

Laboratory Studies

Extensive animal studies have been carried out on the effects of NCC in various kinds of arthritis—especially in horses and dogs, two species in which arthritis is common. After 90 days on a 10 mg dose of NCC, obese arthritic dogs showed significant decreases in overall pain, in pain during manipulation of a limb, and in lameness after exertion.

Longer-term studies have shown that after taking NCC for 120 days, animals experienced a 62% reduction in overall pain, a 91% reduction in pain caused by limb manipulation, and a 78% reduction in exercise-associated lameness. No ill effects or adverse events were seen in any of these studies.

Evaluation of NCC in arthritic dogs has been carried out using a high-tech, piezo-electric ground force plate that measures how much weight the animal is putting on each limb and how hard the animal is able to push against the ground as it walks. These studies showed that NCC-supplemented dogs had significant improvements in both measurements, demonstrating a reduction in arthritis-related pain.

Horses given NCC treatments experienced similar benefits. In one study, horses given placebo treatments showed no change in symptoms attributed to arthritis, while the horses given NCC treatments experienced an 88% reduction in overall pain and a 78% reduction in pain caused by limb manipulation. Again, the treatments were well tolerated and free of side effects.

WHAT YOU NEED TO KNOW
Millions of Americans suffer from arthritis, yet medications make no real change in the course of the disease.Anti-Arthritis Vaccine

Scientists have now discovered that both osteoarthritis and rheumatoid arthritis are caused when the body launches an autoimmune attack against exposed fragments of collagen.

Un-denatured type II collagen,” or “NCC”, is a protein supplement that acts against the autoimmune reactions that can lead to join pain and degeneration.

Animal and human studies convincingly demonstrate that induction of oral tolerance with NCC reduces pain and improves joint function in osteoarthritis and, more recently, in people without arthritis but who suffer joint pain and stiffness following exercise.

NCC is safe and well tolerated; it should form part of every serious joint health program.

Relief for Osteoarthritis Pain

Human clinical trials of NCC demonstrate similar effectiveness in adults suffering from osteoarthritis.

In one study, patients with knee osteoarthritis received NCC or standard treatment for 90 days. The supplemented group experienced a 33% reduction in their osteoarthritis compared to standard therapy recipients. NCC reduced the patients’ self-determined pain scale scores by 40%, compared with just 15.4% in those receiving standard care. And NCC improved joint function by 20%, compared with 6% for usual care.

IMPACT OF ARTHRITIS ON US POPULATION

  • 53.8 million adults were affected by arthritis in 2011
  • 67 million adults are expected to be affected by 2030
  • 22% of US adults suffer from arthritis
  • 33.8% of obese women have arthritis
  • 25.2% of obese men have arthritis
  • 30% of adults suffer from some type of joint pain

Improving Exercise-Induced Joint Pain

Of course, arthritis is just one of many causes of joint pain, which is why researchers in California recently conducted a study of oral NCC in healthy adults who did not have arthritis. These subjects had no knee pain at rest, but reported significant knee pain after exercise. The patients underwent a similar exertion test at each of 7 visits over a 120-day period.

Compared to their performance at the beginning of the study, by days 90 and 120, the subjects that had supplemented with 40 mg NCC could exercise for significantly longer before experiencing joint pain; no such changes were seen in the placebo group.4 Supplemented subjects recovered from their joint discomfort significantly faster than the placebo recipients at days 60, 90, and 120.

The same new study evaluated joint flexibility and determined that the average knee extension was significantly greater in the NCC group than in the placebo group at day 120. Importantly, NCC recipients had significant increases in their knee extension compared to their own baseline level, with no such changes seen among placebo recipients.

In this study published in 2013, the researchers concluded that UC-II® was “more effective than placebo in supporting joint comfort, flexibility, and mobility.”

The broad-spectrum safety of NCC has been evaluated by a number of toxicological assays. It causes no mutations in bacterial genomes, a standard screen for carcinogenicity, and is not associated with oral toxicity.

How it Works

NCC works through something called oral tolerance, which is the desensitization of immune response to specific agents via an orally administered intervention. In this way, NCC reverses T-cell attacks on exposed cartilage.

This makes sense, considering that when researchers want to produce an animal model of human arthritis, they inject small quantities of collagen. The immune system responds by ramping up production of cells that react to collagen. Those cells then attack normal, healthy joint tissue, producing symptoms and signs of arthritis.

Remarkably, however, if the animals are first given a small oral dose of collagen, the incidence of experimentally induced arthritis plummets. And the severity of joint disease is reduced in the animals that do develop arthritis. This phenomenon, called “oral tolerance,” relies on what’s known as gut-associated lymphoid tissue. Clumps of this tissue are found in the human intestinal tract; they are instrumental in “presenting” the oral collagen fragments to the immune system, which then suppresses its response to the protein.

Oral tolerance has other benefits as well, including fighting food allergies through careful exposure to the offending foods. A similar methodology is under investigation for boosting the immune response to certain cancers, especially those of the intestinal tract (mushroom extracts are used there).

Pre-treatment with NCC , in other words, may be inducing immune tolerance even in healthy adults, protecting them from deleterious exposure to their own cartilage.

We don’t react to our own cartilage normally because, in intact joints, there’s a barrier between blood and cartilage so that immune system cells in the blood don’t “see” cartilage proteins. In the aging joint, this protective barrier between blood and cartilage diminishes.

NCC offers a different approach to modifying joint inflammation rather than simply masking the symptoms.

Summary

Arthritis leads the list of conditions that cause disability among American adults. Standard medical treatment consists mainly of treating the symptoms, with few tolerable drugs that modify the course of the disease. A low-cost nutritional supplement has the ability to address the root cause of joint pain—reducing joint pain and improving flexibility. Called “un-denatured type II collagen,” or “NCC,” this natural protein supplement acts against the autoimmune reactions that can lead to join pain and degeneration. NCC has demonstrated efficacy in animal and human studies of arthritis—and can even reduce joint pain and improve joint flexibility in healthy people who experience painful joints after exercise. The implications cannot be overstated; the ability to move comfortably and engage in regular physical activity is critical to maintaining health in the face of our national epidemic of obesity, diabetes, and cardiovascular diseases.

IMPORTANT NOTE

Not all collagen is equal in its ability to fight joint pain. There are two types of collagen: denatured collagen (collagen that’s been disrupted by heat or chemical treatment) and undenatured collagen. An experimental model of autoimmune arthritis showed that “denatured” collagen had no effect on the incidence or severity of the disease.

But the specially-processed undenatured type II collagen (NCC) is more effective because it’s uniquely designed to preserve the 3-dimensional structure of type II collagen. Immune cells in the intestine rely on 3-D shapes to recognize and respond to the signals that turn them on or off. NCC provides the correct 3-D structures to intestinal immune cells, triggering the signaling required for the development of immune tolerance.

 


Patented Ingredient in Flex Helps Protect Against Arthritis

A staggering 53 million Americans suffer from arthritis, making it the leading cause of disability in this country.

A nutritional compound (featured in ActiveBlendz Flex) has demonstrated the ability to address one of the root causes of joint pain—reducing pain and improving flexibility—with none of the side effects of typical drug treatments.

Called “un-denatured type II collagen,” or “UC-II®,” this protein compound acts against the autoimmune reactions that can lead to joint pain and degeneration. UC-II® has been shown effective in previous animal and human studies of arthritis.

A groundbreaking new study shows that UC-II® can reduce joint pain and improve joint flexibility even in healthy people who experience painful joints after exercise.

An Underlying Cause of Osteoarthritisosteoarthritis-inflammation

While the term “arthritis” can be used to describe several different conditions, the two most common forms areosteoarthritis and rheumatoid arthritis.

Rheumatoid arthritis is an autoimmune disease in which the body reacts to components in joint tissue (mainly collagen) to produce inflammation, pain, and disability.

Osteoarthritis was traditionally thought to be the result of wear and tear on the joints.10 Recent discoveries, however, have determined that osteoarthritis is accompanied by the same pro-inflammatory immune factors involved in rheumatoid arthritis.

In both conditions, an autoimmune response is caused when the body launches an attack against collagen, the substance that makes up the bulk of the cartilage that lines your joints.1 Collagen is a protein critical to reducing friction and keeping joints youthful. The problem occurs when microscopic bits of collagen find their way into the bloodstream, at which point immune cells mistakenly identify them as invasive, foreign molecules.

In response to this perceived “threat,” inflammatory cytokines are released that draw in more“killer” T-cells. Those cells bombard exposed cartilage with toxic chemicals in order to destroy it, creating oxidative stress and further inflammation in the process.

Over time, these continuous attacks erode and disintegrate the cartilage that lubricates and functions as a shock-absorber in joints.

The resulting pain can become chronic and debilitating, and can include sensations of friction or grinding involved in joint movement. While less acute at rest, this pain is exacerbated by walking, standing, or any form of weight-bearing. Osteoarthritis sufferers often experience joint stiffness or immobility after periods of inactivity.

Fortunately, scientists have discovered a substance called un-denatured type II collagen, or UC-II®, that retrains killer T-cells so that they recognize collagen as a harmless substance—preventing the joint damage seen in osteoarthritis.

Reducing Joint Pain and Swelling

UC-II® was discovered when a team of scientists at the University of Nebraska found that chicken soup prevented the mobilization of immune system cells to sites of inflammation. Upon further analysis, they discovered that it was not vegetables, but a component of the chicken broth itself that exerted this anti-inflammatory activity.

The researchers showed that chicken-derived type II collagen functions to regulate the immune system so that it stops attacking proteins normally found in healthy joint cartilage.

The results have been remarkable.

In a pilot study of people with severe joint pain, a dose of 10 mg/day of this type II collagen (UC-II®) for 42 days was shown to significantly reduce joint pain and swelling, along with morning stiffness, stiffness following periods of rest, pain that worsens with use of the affected joint, and loss of range of motion and function.

Follow-up studies show UC-II® reduces joint pain and stiffness that can follow as a result of exercise.4 Even normal exercise puts stress on joints, which causes the release of collagen fragments into the bloodstream.16-19 Since these fragments are partly to blame for post-exercise pain and stiffness,16-19 supplementing with UC-II® can prevent post-exercise pain.

Laboratory Studies

Extensive animal studies have been carried out on the effects of UC-II® in various kinds of arthritis—especially in horses and dogs, two species in which arthritis is common. After 90 days on a 10 mg dose of UC-II®, obese arthritic dogs showed significant decreases in overall pain, in pain during manipulation of a limb, and in lameness after exertion.14729969_l

Longer-term studies have shown that after taking UC-II® for 120 days, animals experienced a 62% reduction in overall pain, a 91% reduction in pain caused by limb manipulation, and a 78% reduction in exercise-associated lameness.8No ill effects or adverse events were seen in any of these studies.

Evaluation of UC-II® in arthritic dogs has been carried out using a high-tech, piezo-electric ground force plate that measures how much weight the animal is putting on each limb and how hard the animal is able to push against the ground as it walks. These studies showed that UC-II ®-supplemented dogs had significant improvements in both measurements, demonstrating a reduction in arthritis-related pain.

Horses given UC-II® treatments experienced similar benefits. In one study, horses given placebo treatments showed no change in symptoms attributed to arthritis, while the horses given UC-II® treatments experienced an 88%reduction in overall pain and a 78% reduction in pain caused by limb manipulation.21 Again, the treatments were well tolerated and free of side effects.

WHAT YOU NEED TO KNOW

Millions of Americans suffer from arthritis, yet medications make no real change in the course of the disease.

Scientists have now discovered that both osteoarthritis and rheumatoid arthritis are caused when the body launches an autoimmune attack against exposed fragments of collagen.

Un-denatured type II collagen,” or “UC-II®,” is a protein supplement that acts against the autoimmune reactions that can lead to join pain and degeneration.

Animal and human studies convincingly demonstrate that induction of oral tolerance with UC-II® reduces pain and improves joint function in osteoarthritis and, more recently, in people without arthritis but who suffer joint pain and stiffness following exercise.

UC-II® is safe and well tolerated; it should form part of every serious joint health program.

35653236_lRelief for Osteoarthritis Pain

Human clinical trials of UC-II® demonstrate similar effectiveness in adults suffering from osteoarthritis.

In one study, patients with knee osteoarthritis received UC-II® or standard treatment for 90 days. The supplemented group experienced a 33% reduction in their osteoarthritis compared to standard therapy recipients. UC-II® reduced the patients’ self-determined pain scale scores by 40%, compared with just 15.4% in those receiving standard care. And UC-II ® improved joint function by 20%, compared with 6% for usual care.

 

IMPACT OF ARTHRITIS ON US POPULATION

  • 53.8 million adults were affected by arthritis in 2011
  • 67 million adults are expected to be affected by 2030
  • 22% of US adults suffer from arthritis
  • 33.8% of obese women have arthritis
  • 25.2% of obese men have arthritis
  • 30% of adults suffer from some type of joint pain

Improving Exercise-Induced Joint Pain24841048_l

Of course, arthritis is just one of many causes of joint pain, which is why researchers in California recently conducted a study of oral UC-II® in healthy adults who did not have arthritis. These subjects had no knee pain at rest, but reported significant knee pain after exercise. The patients underwent a similar exertion test at each of 7 visits over a 120-day period.

Compared to their performance at the beginning of the study, by days 90 and 120, the subjects that had supplemented with 40 mg UC-II® could exercise for significantly longer before experiencing joint pain; no such changes were seen in the placebo group. Supplemented subjects recovered from their joint discomfort significantly faster than the placebo recipients at days 60, 90, and 120.

The same new study evaluated joint flexibility and determined that the average knee extension was significantly greater in the UC-II ® group than in the placebo group at day 120. Importantly, UC-II® recipients had significant increases in their knee extension compared to their own baseline level, with no such changes seen among placebo recipients.

In this study published in 2013, the researchers concluded that UC-II® was “more effective than placebo in supporting joint comfort, flexibility, and mobility.”

The broad-spectrum safety of UC-II® has been evaluated by a number of toxicological assays. It causes no mutations in bacterial genomes, a standard screen for carcinogenicity, and is not associated with oral toxicity.

Related UC-II studies:

 

 


© 2018 Javita International Ltd. All rights reserved.  |  Visit Javita Corporate Website